doi: 10.1002/mrm.1910360612 269 PiyanovaA.LomazzoE.BindilaL.LernerR.AlbayramO.RuhlT.et al
Among them, retatrutide has shown significant clinical advantages in phase II clinical trials, reducing the weight of obese patients by up to 24.2% in 48 weeks and lowering the HbA1c of type 2 diabetes patients by 2.2% in 36 weeks (49, 50)
The potential for increased side effects, cardiovascular risks, and the lack of comprehensive research make it crucial to consult a healthcare provider before considering this approach
Products are sourced from third-party manufacturers and supplied as research materials only
The efficacy of N-acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis
NAC significantly reduced the accumulation of ROS, lipid peroxidation and DNA oxidation by approximately 87%, 79%, and 77%, respectively, reducing oxidative stress and increasing antioxidants (67)